Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month High – Should You Buy?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $63.97 and last traded at $63.4950, with a volume of 759374 shares trading hands. The stock had previously closed at $60.54.

Wall Street Analysts Forecast Growth

XENE has been the subject of a number of research reports. Wedbush lowered their price target on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday. Royal Bank Of Canada lifted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Wells Fargo & Company reissued an “overweight” rating and set a $69.00 price target on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Finally, Needham & Company LLC cut their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $77.20.

Xenon Pharmaceuticals Price Performance

The company has a market capitalization of $6.79 billion, a PE ratio of -14.93 and a beta of 0.61. The company’s fifty day moving average is $55.59 and its 200-day moving average is $50.77.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the business posted ($0.83) EPS. Equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current fiscal year.

Insider Transactions at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. The trade was a 5.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Cinctive Capital Management LP grew its stake in Xenon Pharmaceuticals by 1.1% during the 4th quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after buying an additional 263 shares during the last quarter. State of Wyoming raised its stake in Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 350 shares during the last quarter. Quarry LP boosted its holdings in Xenon Pharmaceuticals by 25.0% in the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 500 shares in the last quarter. Altfest L J & Co. Inc. boosted its holdings in Xenon Pharmaceuticals by 6.5% in the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock worth $369,000 after acquiring an additional 501 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Xenon Pharmaceuticals by 0.7% during the first quarter. Royal Bank of Canada now owns 90,387 shares of the biopharmaceutical company’s stock worth $5,255,000 after acquiring an additional 630 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.